BIA letter to the Chancellor ahead of the 2019 Spending Round

Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae; PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects

Dr Mahony will work with the UK Government to champion investment into the UK’s innovative life sciences and biotech sector, including playing a key role in the ongoing pension reforms led by Chancellor Rachel Reeves MP.

Pension reform unlocks cash for UK life sciences, London Life Sciences Week and #bioProcessUK are here.

Scancell announces strengthening of leadership team as it closes on value-generating inflection points

MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney disease (DKD) patients.

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy); Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL